TrueBlue is a ≈$140M-cap light industrial staffing company (PeopleReady, PeopleManagement, PeopleScout). On April 13, 2026, it filed an 8-K disclosing an activist settlement — the kind of filing often read as governance housekeeping. Buried in the 10.1 exhibit and 99.1 press release: legally-binding 2026 financial targets, a bulge-bracket financial advisor, and "unsolicited offer" language not typical of cooperation agreement disclosures.

What the filing says

TBI and EHS Azure Opportunity Fund (Eric Su, former IAC Head of M&A and former partner at Marcato; counsel: Olshan Frome Wolosky) signed a cooperation agreement on April 10, 2026. EHS held 2.9% (896,023 shares), had filed director nominations Jan 16 and a books-and-records demand Jan 23 — both withdrawn. EHS gets one new independent director appointed by Sept 30, 2026 and two Board presentation slots. Standstill caps EHS at 7.5%.

Section 10 embeds hard 2026 thresholds: Adjusted EBITDA ≥ $24M (with a $12M adjustment cap; non-cash impairment excluded from the cap) AND revenue ≥ $1.64B. Meet both and the standstill extends through the 2028 proxy cycle. Miss either and EHS can renominate ≈14 days after 2026 audited financials release.

Two signals less obvious on first read:

• Barclays named financial advisor. Bulge-bracket bank retention is not standard for a governance settlement with a 2.9% shareholder.
• Risk factor language: "factors relating to any unsolicited offer ('Offer') to purchase the shares of the Company, actions taken by the Company or its shareholders in respect to such an Offer." This is non-standard boilerplate in cooperation agreement press releases.

What the market thinks

The unsolicited offer reference is not hypothetical. HireQuest (HQI) offered $12.30/share (Feb 2025), then $7.50/share all-stock (May 9, 2025 letter, 61% premium). TBI Board rejected both and adopted a poison pill May 14, 2025 that expires May 13, 2026 — 19 days from the filing date.

Back-solving implied P(deal) from price (assume $3 no-deal fair value, $7 deal fair value):

• Apr 13 filing day, $3.33 → market P(deal) ≈ 8%
• Today (+39% since filing) → market P(deal) ≈ 40%

Stock is +39% in 11 days. RSI 65, mom 1M +29.4%, mom 1W +10.8%.

Fundamental read: P(deal or hostile outcome) ≈ 50%. Edge compressed from ≈35pp to ≈10pp.

Why the gap existed

The signal lived in the 10.1 exhibit (Section 10 termination clause), the 99.1 press release's forward-looking paragraph, and the unannounced Barclays engagement — not in the 8-K cover or bolded headlines. Connecting the "unsolicited offer" language to HQI's 2023-2025 public pursuit required cross-referencing across four filings. Passive flow and retail screened the filing as governance. The gap closed in ≈7 business days.

Risks, ranked

1. Distress tail. TBI converted a $255M cash-flow revolver to a $175M ABL in Feb 2026 — a 31% capacity reduction. The closing 8-K explicitly admitted "payables stretched beyond their customary payment practices" and disclosed only $75M additional availability. If Q1 revenue capture declines, receivables fall, ABL borrowing base shrinks. Scenario grid implies -51% from current in this state.
2. HQI silence. HQI's March 2026 10-K does not mention TBI. The two-year pursuer may have yielded after two public rejections. No evidence of a competing bidder.
3. Board entrenchment. Board rejected $12.30 and $7.50 and adopted the pill same-day as public rejection. Sidley Austin advising defense. Extending the pill is within Board authority.
4. Cyclical headwind. Buyers discount staffing at rising-unemployment prints. HQI's $7.50 offer in May 2025 was tied to a higher revenue base.

Catalysts

• May 5-8 (est): Q1 2026 earnings — ABL utilization, revenue capture rate
• May 13: Poison pill expires. Extend = defense continues. Lapse = accumulation path opens
• June-August: 2026 annual meeting, two existing directors depart, new independent director seated
• Sept 30: EHS-aligned director finalized
• Q1 2027: 2026 audited financials determine EHS standstill extension vs renomination

What would change the picture

• Bullish: HQI public re-engagement (letter, 13D, 8-K) before June 30. New 5%+ activist 13D. Barclays-attributed press reports naming PE or strategic suitors. Q1 revenue +YoY with stable ABL draw.
• Bearish: Q1 revenue miss with ABL draw approaching $100M. Pill extension announced with institutional pushback muted. HQI capital raise unrelated to TBI (signals pursuit is over).

Forward expected return from current price is ~+0.4% over 120 days against a 15% probability of a -50% distress leg. The thesis was right. The entry window was 5-7 business days.

Evidence